Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

Schmitz, 2002, Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial, Lancet, 359, 2065, 10.1016/S0140-6736(02)08938-9 Moskowitz, 2018, Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse, Blood, 132, 2639, 10.1182/blood-2018-07-861641 Moskowitz, 2015, Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 385, 1853, 10.1016/S0140-6736(15)60165-9 Moskowitz, 2015, PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study, Lancet Oncol, 16, 284, 10.1016/S1470-2045(15)70013-6 Herrera, 2018, Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma, Ann Oncol, 29, 724, 10.1093/annonc/mdx791 LaCasce, 2018, Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma, Blood, 132, 40, 10.1182/blood-2017-11-815183 Connors, 2018, Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma, N Engl J Med, 378, 331, 10.1056/NEJMoa1708984 Ramsey, 2016, Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma, Br J Haematol, 175, 860, 10.1111/bjh.14316 Green, 2010, Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, Blood, 116, 3268, 10.1182/blood-2010-05-282780 Roemer, 2016, PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome, J Clin Oncol, 34, 2690, 10.1200/JCO.2016.66.4482 Armand, 2018, Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial, J Clin Oncol, 36, 1428, 10.1200/JCO.2017.76.0793 Chen, 2017, Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma, J Clin Oncol, 35, 2125, 10.1200/JCO.2016.72.1316 Moskowitz, 2021, Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma, J Clin Oncol, 39, 3109, 10.1200/JCO.21.01056 Armand, 2019, PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation, Blood, 134, 22, 10.1182/blood.2019000215 Herrera, 2018, Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma, Blood, 131, 1183, 10.1182/blood-2017-10-811224 Cheson, 2020, Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial, Lancet Haematol, 7, e808, 10.1016/S2352-3026(20)30275-1 Cheson, 2014, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 32, 3059, 10.1200/JCO.2013.54.8800 Marouf, 2022, Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study, Haematologica, 107, 1681, 10.3324/haematol.2021.279564 Allen, 2021, Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma, Blood, 137, 1318, 10.1182/blood.2020007400 Bröckelmann, 2020, Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial, JAMA Oncol, 6, 872, 10.1001/jamaoncol.2020.0750 Kumar, 2021, Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma, J Clin Oncol, 39, 2257, 10.1200/JCO.21.00108 Fedorova, 2019, Retreatment with nivolumab in patients with R/R classical Hodgkin lymphoma after discontinuation of the therapy with immune checkpoint inhibitors, Hematol Oncol, 37, 496, 10.1002/hon.176_2631 Bartlett, 2014, Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies, J Hematol Oncol, 7, 24, 10.1186/1756-8722-7-24 Skarbnik, 2021, Safety and efficacy of consolidation therapy with ipilimumab plus nivolumab after autologous stem cell transplantation, Transplant Cell Ther, 27, 391, 10.1016/j.jtct.2020.12.026 Lane, 2012, Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant, Leuk Lymphoma, 53, 1130, 10.3109/10428194.2011.645208 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Moskowitz, 2010, Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma, Blood, 116, 4934, 10.1182/blood-2010-05-282756 Moskowitz, 2012, Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma, Blood, 119, 1665, 10.1182/blood-2011-10-388058 Sasse, 2019, Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment, Haematologica, 104, e21, 10.3324/haematol.2018.196279 Hollander, 2018, Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma, PLoS One, 13, e0204870, 10.1371/journal.pone.0204870